Hemispherian Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Later Stage VC
- Investors
-
11
Hemispherian General Information
Description
Operator of a biotechnology company intended to develop treatments for aggressive types of cancer. The company engages in developing personalized cancer therapies to fight glioblastoma multiforme tumors and is developing a novel class of small-molecule drugs, enabling physicians to get access to novel drugs in areas of unmet medical need.
Contact Information
Website
www.hemispherian.comCorporate Office
- Lørenveien 73
- 0585 Oslo
- Norway
Corporate Office
- Lørenveien 73
- 0585 Oslo
- Norway
Hemispherian Timeline
Hemispherian Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Jun-2024 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 15-Dec-2023 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series A1) | 24-Nov-2022 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 15-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 03-May-2022 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 04-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 28-Sep-2020 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 12-Jun-2020 | $133K | Completed | Pre-Clinical Trials | ||
| 1. Accelerator/Incubator | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Hemispherian Patents
Hemispherian Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024261243-A1 | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer | Inactive | 21-Jun-2023 | ||
| GB-201917499-D0 | Methods of synthesis | Inactive | 29-Nov-2019 | ||
| GB-201901427-D0 | Cancer therapies | Active | 01-Feb-2019 | ||
| GB-2580963-A | Cancer therapies | Active | 01-Feb-2019 | ||
| GB-2580963-B | Cancer therapies | Active | 01-Feb-2019 | A61K31/7068 |
Hemispherian Signals
Hemispherian Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Locapes Investment Fund | Venture Capital | Minority | ||
| Kistefos | PE/Buyout | Minority | ||
| Kvantia | Hedge Fund | Minority | ||
| Angel (individual) | Minority | |||
| European Innovation Council | Accelerator/Incubator | Minority |
Hemispherian Investments (1)
Hemispherian’s most recent deal was a Joint Venture with GLIX1. The deal was made on 29-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GLIX1 | 29-Sep-2025 | Joint Venture | Drug Discovery |
Hemispherian FAQs
-
When was Hemispherian founded?
Hemispherian was founded in 2015.
-
Where is Hemispherian headquartered?
Hemispherian is headquartered in Oslo, Norway.
-
What is the size of Hemispherian?
Hemispherian has 11 total employees.
-
What industry is Hemispherian in?
Hemispherian’s primary industry is Drug Discovery.
-
Is Hemispherian a private or public company?
Hemispherian is a Private company.
-
What is Hemispherian’s current revenue?
The current revenue for Hemispherian is .
-
How much funding has Hemispherian raised over time?
Hemispherian has raised $4.7M.
-
Who are Hemispherian’s investors?
Locapes Investment Fund, Kistefos, Kvantia, , and European Innovation Council are 5 of 11 investors who have invested in Hemispherian.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process